Microbot Medical stock gets a USD 6.33 consensus target after revision
Published on 10/08/2026 at 02:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Microbot Medical (ISIN US59503A2042) was last at USD 1.12 on Nasdaq on October 7, 2026, up 4.67 percent, while its average analyst target stood at USD 6.33 after a revision. The contrast puts commercialization progress and execution risk at the center of the MBOT story.
Analyst target falls to USD 6.33
According to Simply Wall St on September 25, 2026, the average target from three analysts fell from USD 7.00 to USD 6.33. At the October 7 price of USD 1.12, the target lies 465.2 percent above the price.
The revision matters because the target moved lower even as Microbot advances the commercial rollout of its LIBERTY Endovascular Robotic System. The source also described the company as unprofitable, making sales conversion and hospital adoption central valuation variables.
Q2 revenue reaches USD 241,000
Microbot reported second-quarter 2026 revenue of USD 241,000 and GAAP earnings per share of negative USD 0.08 on August 11, 2026, according to MarketBeat. Revenue was USD 105,000 in the first quarter, so the sequential increase was 129.5 percent, while the quarterly loss remained a key counterweight.
The company described the second-quarter increase as driven by repeat orders, greater use among existing customers and new customers following the LIBERTY full-market release. The figures show an early commercial ramp, but the loss profile leaves manufacturing scale and recurring procedure volume as important tests.
Israel adds a new market
On October 6, 2026, Microbot announced a three-year exclusive commercial distribution agreement with Medtechnica for Israel, according to GlobeNewswire. Medtechnica can market and sell LIBERTY throughout the country, while initial orders are anticipated in the fourth quarter of 2026.
Microbot said Israeli regulatory approval and device registration were completed in May 2026. The agreement expands the addressable commercial footprint beyond the United States, but revenue timing still depends on distributor orders and hospital adoption.
MBOT stays near its yearly low
Microbot's October 7 price of USD 1.12 was above the same-session low of USD 1.07 and below the high of USD 1.16. Its 52-week range was USD 1.05 to USD 3.30, while market capitalization was USD 51.0 million and volume reached 638,795 shares on Nasdaq.
For investors, the central comparison is clear: Q2 revenue rose 129.5 percent from Q1, but the average analyst target fell to USD 6.33 and the company remained loss-making. The next evidence will come from the pace of Israeli orders and the conversion of LIBERTY interest into repeat procedures.
Microbot Medical stock facts
- Company: Microbot Medical Inc.
- ISIN: US59503A2042
- Ticker: MBOT
- Trading venue: Nasdaq Capital Market
- Price (as of October 7, 2026, 4:00 p.m. ET): USD 1.12
- Market capitalization: USD 51.0 million (as of October 7, 2026)
- 52-week range: USD 1.05-3.30 (as of October 7, 2026)
- Sector / Industry: Health care / Medical devices
